Akari Therapeutics Plc Sponsored ADR AKTX 深 滬
已收盤 02-06 16:00:00 美东时间
0.235
+0.010
+4.44%
華盛通- 最 高0.2479
- 今 開0.225
- 成交量 16.71万股
- 最 低 0.221
- 昨 收 0.225
- 總市值 1075.91万
- 52周最高 1.73
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 0.2178
- 委 比 -92.86%
- 總股本 4578.35万
- 歷史最高 2380.00
- 量 比 0.94
- 振 幅 11.96%
- 歷史最低 0.2178
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akari Therapeutics Files U.S. Provisional Patent Application Covering Second Pipeline Candidate, AKTX-102, ADC Directed Against CEACAM5
Company expands its ADC pipeline and patent estate for novel, differentiated ADCsNew pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of
01-26 21:46
Akari Therapeutics plc Announces Date for Upcoming Shareholder Meeting
Akari Therapeutics plc Announces Date for Upcoming Shareholder Meeting Akari Therapeutics plc has scheduled a general meeting of shareholders to be held on March 2, 2026, at 75/76 Wimpole Street, London. Shareholders will have the opportunity to vote on resolutions proposed by the Board of Directors
01-23 22:12
Akari Therapeutics to Present at the 2026 Biotech Showcase
Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the 2026 Biotech Showcase on January 13, 2026, at 9:30 AM PST. His presentation will cover Akari's ADC platform, strategic priorities, and key milestones for 2026. Akari is developing next-generation ADCs with a unique RNA-splicing payload, PH1, targeting cancer cells. The lead candidate, AKTX-101, shows potential in preclinical studies and is expected to begin its firs...
01-08 14:15
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market a...
2025-12-31 19:14
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Akari Therapeutics reported significant progress in 2025, advancing its innovative ADCs with PH1 payload, demonstrating potent anti-tumor activity and immune activation. AKTX-101, targeting Trop2, showed efficacy in pancreatic, prostate, bladder, and gastric cancers. The company partnered with WuXi XDC to initiate GMP manufacturing for Phase 1 trials expected in late 2026/early 2027. Akari also strengthened its IP portfolio and engaged aScientifi...
2025-12-30 14:15
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 9.3% to $...
2025-12-24 05:05
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Therapeutics partners with WuXi XDC for GMP manufacturing of AKTX-101, its lead ADC program featuring the novel PH1 payload. This collaboration aims to advance clinical trials and achieve regulatory milestones. WuXi XDC's expertise in ADC development supports Akari's goal of initiating a Phase 1 study in late 2026 or early 2027. The PH1 payload offers a unique approach combining cytotoxicity and immuno-oncology effects, potentially enhancin...
2025-12-23 13:30
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Akari Therapeutics CEO participated in a Virtual Investor "What This Means" segment, discussing the company's novel spliceosome modulating payload, PH1, and its potential in treating tough cancers. The segment highlighted new preclinical data showing therapeutic potential of lead ADC AKTX-101 in hard-to-treat KRAS-mutant pancreatic cancer, with plans for clinical testing by late 2026/early 2027. AKTX-101 targets Trop2 receptor, delivering PH1 pay...
2025-12-18 13:30
Akari Therapeutics Announces $5M Financing Agreement
Akari Therapeutics ( ($AKTX) ) has provided an announcement. Akari Therapeutics...
2025-12-17 23:48
Akari Therapeutics Approves Key Resolutions at Meeting
Akari Therapeutics ( ($AKTX) ) just unveiled an announcement. On December 15, 2...
2025-12-17 06:21
